Glial fibrillary acidic protein and multiple sclerosis progression independent of acute inflammation.
Multiple sclerosis
biomarker
disability progression
glial fibrillary acidic protein
neurofilament light chain
non-inflammatory
Journal
Multiple sclerosis (Houndmills, Basingstoke, England)
ISSN: 1477-0970
Titre abrégé: Mult Scler
Pays: England
ID NLM: 9509185
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
medline:
10
8
2023
pubmed:
15
6
2023
entrez:
15
6
2023
Statut:
ppublish
Résumé
The clinical relevance of serum glial fibrillary acidic protein (sGFAP) concentration as a biomarker of MS disability progression independent of acute inflammation has yet to be quantified. To test whether baseline values and longitudinal changes in sGFAP concentration are associated with disability progression without detectable relapse of magnetic resonance imaging (MRI) inflammatory activity in participants with secondary-progressive multiple sclerosis (SPMS). We retrospectively analyzed longitudinal sGFAP concentration and clinical outcome data from the Phase 3 ASCEND trial of participants with SPMS, with no detectable relapse or MRI signs of inflammatory activity at baseline nor during the study ( We found a significant cross-sectional association between baseline sGFAP and sNfL concentrations and T2 lesion volume. No or weak correlations between sGFAP concentration and changes in EDSS, T25FW, and 9HPT, or CDP were observed. Without inflammatory activity, changes in sGFAP concentration in participants with SPMS were neither associated with current nor predictive of future disability progression.
Sections du résumé
BACKGROUND
The clinical relevance of serum glial fibrillary acidic protein (sGFAP) concentration as a biomarker of MS disability progression independent of acute inflammation has yet to be quantified.
OBJECTIVE
To test whether baseline values and longitudinal changes in sGFAP concentration are associated with disability progression without detectable relapse of magnetic resonance imaging (MRI) inflammatory activity in participants with secondary-progressive multiple sclerosis (SPMS).
METHODS
We retrospectively analyzed longitudinal sGFAP concentration and clinical outcome data from the Phase 3 ASCEND trial of participants with SPMS, with no detectable relapse or MRI signs of inflammatory activity at baseline nor during the study (
RESULTS
We found a significant cross-sectional association between baseline sGFAP and sNfL concentrations and T2 lesion volume. No or weak correlations between sGFAP concentration and changes in EDSS, T25FW, and 9HPT, or CDP were observed.
CONCLUSION
Without inflammatory activity, changes in sGFAP concentration in participants with SPMS were neither associated with current nor predictive of future disability progression.
Identifiants
pubmed: 37317870
doi: 10.1177/13524585231176732
pmc: PMC10413790
doi:
Substances chimiques
Glial Fibrillary Acidic Protein
0
Biomarkers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1070-1079Références
Mult Scler. 2015 Apr;21(5):550-61
pubmed: 25732842
Glia. 2007 Oct;55(13):1300-12
pubmed: 17626262
Mult Scler Relat Disord. 2021 May;50:102931
pubmed: 33926692
JAMA Neurol. 2023 Feb 6;:
pubmed: 36745446
Acta Neurol Scand. 2014 Aug;130(2):81-9
pubmed: 24571714
JAMA Netw Open. 2022 Feb 1;5(2):e2147588
pubmed: 35133438
Mult Scler Relat Disord. 2021 Jun;51:102870
pubmed: 33819724
Neuropatol Pol. 1992;30(1):73-80
pubmed: 1484610
Sci Rep. 2018 Oct 4;8(1):14798
pubmed: 30287870
BMJ Neurol Open. 2022 Jun 7;4(1):e000240
pubmed: 35720980
Nat Rev Neurol. 2022 Mar;18(3):158-172
pubmed: 35115728
Trends Neurosci. 2015 Jun;38(6):364-74
pubmed: 25975510
Mult Scler. 2022 Oct;28(11):1685-1696
pubmed: 36059263
Ann Neurol. 2015 Nov;78(5):710-21
pubmed: 26239536
Mult Scler Relat Disord. 2021 May;50:102810
pubmed: 33556656
Mult Scler. 2019 Dec;25(14):1915-1925
pubmed: 30566027
Mult Scler. 2020 Feb;26(2):210-219
pubmed: 30570436
Front Neurol. 2019 Mar 26;10:280
pubmed: 30972011
Neurol Neuroimmunol Neuroinflamm. 2022 Nov 14;10(1):
pubmed: 36376097
Sci Rep. 2020 Jul 2;10(1):10923
pubmed: 32616916
Neurology. 2004 Nov 9;63(9):1586-90
pubmed: 15534240
Brain. 2005 Nov;128(Pt 11):2705-12
pubmed: 16230320
J Neurol. 2011 May;258(5):882-8
pubmed: 21197541
Nat Rev Neurol. 2018 Oct;14(10):577-589
pubmed: 30171200
Lancet Neurol. 2018 May;17(5):405-415
pubmed: 29545067
Brain Res. 1971 May 7;28(2):351-4
pubmed: 5113526